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Abstract
Stroke is a major healthcare problem ranking as the third leading cause
of death and the first cause of disability in the Western countries. Although
young adults are at a lower risk of stroke compared to older people, strokes
affecting those who are at earlier stages of their productive lives have a
greater social impact in terms of number of years of lost productivity and
disability. The incidence of stroke in young people ranges between 60 to 200
new cases per year per one million inhabitants, and the overall incidence is
about one episode per 100,000 patients per year. Stroke in the young is more
frequent in change with industrialized countries, in women, and in blacks
and Hispanics compared to whites. In this review we sought to discuss the
risk factors, and specific diseases and causes associated with stroke in the
young. Moreover, we will discuss the genetic impact on stroke in young, and
the outcome and prognosis after stroke among young adults.
1. INTRODUCTION AND EPIDEMIOLOGY
Stroke is a major healthcare problem ranking as the third leadingcause of death and the first cause of disability in the Western
countries (1). The average age for the incidence of a stroke is >75 years
for women, and 71 years for men as reported by American Heart
Association in the Heart Disease and Stroke Statistics – 2012 Update
(1). Although young adults are at a lower risk of stroke compared to
older people, strokes affecting those who are at earlier stages of their
productive lives have a greater social impact in terms of number of years
of lost productivity and disability. Most of the strokes in the young age
are of an ischemic etiology (1, 2). An important issue is the consistent
definition of „young” to establish a uniform cut-off to use in various
epidemiological studies. Otherwise, comparing the results from dif-
ferent clinical studies in young adults may prove challenging. In fact,
apart from a consensus proposal on the etiological investigation of
cerebral infarction in young adults from the Societé Française Neuro-
vasculaire (3), no other specific guidelines have been proposed for the
management of stroke in this sub-population.
Forty-five years as the upper limit of defining young adults have
been used in various studies and appears to be a reasonable boundary.
The incidence of stroke in young people ranges from 60 to 200 new
cases per year per million inhabitants (2, 4). The overall incidence is
about one event per 100,000 patients per year. The incidence is higher
in non-industrialised countries (2, 4). A Finland study (5) reported a
yearly incidence of stroke increasing from 2.4 per 100,000 for people
aged 20–24 years, to 4.5 per 100,000 for people aged 30–34 years, and to
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Overview
frequent in women aged 20–30 years and in men older
than 35 years. Also race-ethnicity has been demonstrated
to play a role in the incidence of stroke in the young. In
the Northern Manhattan Study (NOMAS) cohort, we
showed that young blacks and Hispanics have signi-
ficantly greater stroke incidences than young whites (6).
Incidence, risk factors, and etiology of stroke in young
adults differ significantly from those observed among
older patients; therefore the knowledge acquired in stu-
dies conducted in elderly people with cerebral infarcts is
often not applicable to younger people afflicted with
stroke. Although, the main clinical challenge in manage-
ment of a young adult with an acute stroke remains the
identification of its cause, our ability to ascertain a speci-
fic etiology has improved greatly in the past few decades
due to advances in non-invasive imaging technologies
that allow a better resolution of the brain vessels, heart
anatomical structures and cardiac function.
2. RISK FACTORS FOR STROKE IN YOUNG
Risk factors and etiology for stroke in young adults
significantly differ from those observed among older in-
dividuals (9). These data are derived mainly from hospi-
tal-based case control studies and less often population-
-based case-control or cohort studies. Traditional vascular
stroke risk factors such as hypertension, dyslipidemia
and diabetes still have a significant role in younger pa-
tients and their role only increases with age. However,
risk factors for stroke which are considered „minor” in
the elderly, have a greater impact on etiology of strokes in
the young (Table 1).
Smoking is an important risk factor for cerebral in-
farction in the young (8). Young adults (15–45yrs old)
who smoke are 1.6 times more likely to have a cerebral
infarction than a non-smoker (95%CI, 1.07 – 2.42) (8).
Moreover, this risk increases with the duration and dose
of the exposure, from an odds ratio (OR) of 2.2 (1.5 – 3.3)
for one to ten cigarettes per day up to 9.1 (3.2 – 26.0) for
40 or more cigarettes per day (9).
Another important risk factor for stroke in the young
is migraine. A recent meta-analysis indicated a signifi-
cantly higher risk for stroke among people who had a
migraine with aura (2.16, 1.53 – 3.03) compared with
people who had migraine without aura (1.23, 0.90 – 1.69;
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TABLE 1
Risk factors, specific diseases and genetic determinants associated with stroke in young.
Risk Factors in Stroke in Young Prevalence References
Hypertension, dyslipidemia, diabetes 45–60% 18, 19
Smoking 40–60% 8, 9
Migraine 10–35% 10
Pregnancy and puerperium 5–10% 12
Oral contraceptives 10–22% 14
Illicit drugs use 3–12% 17
Specific Diseases
Spontaneous arterial dissection 40–52% 20
Fibromuscular dysplasia of carotid and vertebral arteries 10–15% 20, 25, 26
Vasculitis and connective tissue disorders
Churg-Strauss, Wegener’s vasculitis, polyarteritis nodosa, cryoglobulinaemia, Behçet’ disease,




syphilis, tuberculous meningitis, acute bacterial meningitis, Varicella-zoster virus, AIDS, hepatitis C,




paroxysmal nocturnal haemoglobinuria, thrombotic thrombocytopenic purpura, erythrocytosis,




patent forame ovale, atrial septal aneurysm, inter-atrial septum, atrial fibrillation, cardiomyopathy,
valvular disease and endocarditis
18–30% 39, 43, 44
Genetic Determinants
Monogenic determinants
CADASIL, CARASIL, Fabry´s disease, Moyamoya disease
<2% 45, 46, 52
Multifactorial Determinants
variants in the genes for coagulation factor V, prothrombin, methylenetetrahydrofolate reductase




meta-regression for aura status P=0.02) (10). Additional
analyses showed how age less than 45 years, smoking,
and oral contraceptive use have a synergstic effect on risk.
These results were also confirmed in a subgroup from the
Women’s Health Study after adjustment for major vas-
cular risk factors (age, blood pressure, antihypertensive
medication, diabetes, body mass index, smoking, alcohol
consumption, menstrual status, hormone levels, oral con-
traceptive use and cholesterol) (11). A higher incidence
of stroke in young adults has been reported during preg-
nancy and puerperium (12). However, the exactly cause
of the stroke in these patients is often not identified. The
hypercoagulable state associated with changes in vessel
wall function which are typical in pregnancy have been
suggested to play a role in the occurrence of stroke (13).
Moreover, eclampsia, a typical pregnancy-related disease,
has been associated with cerebral vasoconstriction syn-
drome and with non-haemorrhagic stroke-like episodes
(13). The role of oral contraceptives as a risk factor for
stroke in young is still not well defined. A meta-analysis
conducted on six case-control studies showed no increase
in the risk of stroke among women using only pro-
gestogen contraceptives (OR=0.96; 95%CI: 0.70 – 1.31)
(14). However, the risk for stroke increased fourfold for
women who take pills with a high content of estrogen,
and is doubled for those who take pills with low estrogen
content (14). Another meta-analysis demonstrated that
use of oral contraceptive was associated with increased
risk of ischemic stroke (RR, 2.75; 95%CI, 2.24–3.38).
Smaller estrogen dosages were associated with lower risk
(P=0.01 for trend), but risk was still significantly ele-
vated for all dosages. This study concluded that the im-
pact of oral contraceptive may be evaluated as additional
4.1 ischemic strokes per 100,000 non-smoking, normo-
tensive women using low-estrogen OCs, or 1 additional
ischemic stroke per year per 24,000 such women (15).
Unfortunately, in the young population stroke is also
one of the most common complications of drug abuse.
Strokes related to drug abuse may account for up to 12%
of all cases in the young (16). Therefore, without a pre-
cise diagnosis, screening for illicit drugs should be always
done in young patients presenting with stroke. Illicit
drugs increase stroke risk regardless of the administra-
tion routes. Intravenously used drugs may induce embo-
lisation by injection of exogenous and toxic material.
Cocaine or amphetamines may induce stroke by vasocon-
striction, platelet aggregation and heart arrhythmias (17).
A study conducted on 253 consecutive first-ever ische-
mic stroke patients less than 45 years old from Athens
Young Stroke Registry showed that smoking (59%) and
dyslipidemia (41%) were the most frequent vascular risk
factors (18). Recently, another study was conducted to
evaluate the vascular risk factor differences in 3,944 pa-
tients with first-ever ischemic stroke aged 15 to 49 years
from 15 cities in 12 European countries from hospital
registries or population-based studies on young adults
(19). Overall the top 3 most frequent risk factors were
current smoking (49%), dyslipidemia (46%), and hyper-
tension (36%). Interesting, southern European patients
were younger compared to northern Europeans, and in
both sexes, prevalence of family history of vascular risk
factors and cardiovascular disease (CVD) positively cor-
related with age and stroke risk across all regions.
3. SPECIFIC DISEASES AND CARDIAC
PATHOLOGY ASSOCIATED WITH
STROKE IN YOUNG
A number of pathophysiologic factors and specific
disease have been linked to stroke in the young (Table 1).
One of the most common causes of stroke in young
adults is spontaneous arterial dissection (20). Cervical
dissection commonly affects the extracranial internal ca-
rotid artery, starting a few centimetres after the common
carotid bifurcation or the vertebral artery. Dissections are
usually subintimal and their rupture results in a hema-
toma with consequent arterial stenosis or occlusion. The
pathogenesis of arterial dissection is still not clearly defin-
ed. Head and neck trauma may predispose to dissection;
however the incidence of stroke in young with these
traumas is very low. It seems more associated to a con-
comitance between vascular risk factors such as hyper-
tension, and genetic factors (20, 21). We previously report-
ed a case of an ischemic stroke patient with the presence
of intrapetrous right internal carotid artery dissection
and essential thrombocythemia, suggesting that a hema-
tological disorder may cause endothelial dysfunction and
predispose to vascular damage such as carotid artery
dissection (22). The diagnosis of arterial dissection can
be easily made with ultrasound, magnetic resonance imag-
ing (MRI), computer tomography (CT), or catheter an-
giography (23). Usually, the stenotic lesions resolve in
about 70% of cases, whereas recanalization of occluded
arteries is less frequent (24).
Fibromuscular dysplasia (FMD) of carotid and verte-
bral arteries is another potential cause of stroke in young
adults. FMD is nonatherosclerotic, noninflammatory vas-
cular disease that may result in arterial stenosis, occlu-
sion, aneurysm and/or dissection (20, 22, 25). Fibro-
muscular dysplasia is present in abput 15% of patients
with a spontaneous dissection of the carotid or vertebral
artery and most of these patients are at a high risk of
stroke (26) (Figure 1). However, pathophysiology of FMD
is poorly understood and large international FMD regis-
tries are currently ongoing in order to investigate natural
history, diagnosis, treatment and potential role of ge-
netics in FMD.
Other potential causes of stroke in young include
primary vasculitis, inflammatory and connective tissue
disorders. Churg-Strauss, Wegener’s vasculitis, polyarte-
ritis nodosa, cryoglobulinaemia, Behçet’ disease, inflam-
matory bowel disease, and sarcoidosis, all may increase
the risk for stroke in the young (27). However, the most
common immunological disorder associated with stroke
in young is systemic lupus erythematosus, antiphospho-
lipid syndrome (SLE) (28). SLE can manifest itself in
hypertensive small-vessel disease, cardioembolism, and
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the presence of a prothrombotic state as principal risk
factors leading to stroke in affected patients (29).
Infectious diseases have also been linked with stroke
in the young. Syphilis in its late stage can induce stroke
through arteritis of the major brain vessels such as the
middle cerebral artery or the deep perforating vessels
(Nills-Alzheimer’s arteritis), and/or through cardiac com-
plications (30). Cases of stroke have been also reported in
young patients affected by tuberculous meningitis (31),
acute bacterial meningitis (32), Varicella-zoster virus (33),
AIDS (34), cysticercosis (35), and Chagas disease caused
by Trypanosoma cruzi (36).
Impacting the coagulation system’s ability to increas-
ing or decreasing platelet aggregation and therefore the
risk of thrombosis or hemorrhage, hematological diseases
such as paroxysmal nocturnal hemoglobinuria, throm-
botic thrombocytopenic purpura, erythrocytosis, leuke-
mias, and intravascular lymphoma have been associated
with risk of stroke in the young. Among these, the stron-
gest association has been reported for sickle-cell disease
(SCD), especially in childhood (37). The vessel intima’s
proliferation with discontinuity of the internal elastic
lamina associated with a proliferation of endothelial cells
and concomitant thrombus formation has been shown in
pathological examination of diseased vasculopathic seg-
ments from SCD patients (38).
Cardiac causes account for 20% of all strokes in young;
however this percentage is considered a relatively modest
proportion compared to their older counterparts. A diag-
nosis of a cardioembolic stroke is made in patients with
brain infarction in a pattern consistent with an embolus
in the presence of an appropriate cardiac abnormality,
and without another cause for stroke. The risk of embolism
is different for different cardiac lesions. Patent forame
ovale (PFO) is a common remnant of the fetal anatomy,
which is found in 15–25% of the general population.
PFO has been identified as an important etiology of
stroke in young, especially when combined with atrial
septal aneurysm (ASA) (39). A study conducted in a
population of 60 adults under 55 years of age with ischemic
stroke and a normal cardiac examination demonstrated
significantly greater prevalence of PFO in the patients with
stroke (40%) than in the control group (10%, p<0.001)
(40). However, this association was weaker or absent in
older patients (41), and the real impact of PFO in stroke
is still controversial. For example, in 1,100 stroke-free
subjects older than 39 years of age from NOMAS, PFO,
evaluated by transthoracic echocardiography, was not
significantly associated with ischemic stroke (HR 1.64,
95% CI, 0.87 to 3.09) after adjustment for demographics
and risk factors. The same trend was observed in all age,
gender, and race-ethnic subgroups (42). ASA is an addi-
tional abnormality of the inter-atrial septum (IAS), usu-
ally occurring in association with PFO. When present, it
tends to occur in association with larger shunts and has
been demonstrated to be associated with increased risk of
recurrent stroke risk (43).
Minor cardiac pathologies associated with stroke in
young include: atrial fibrillation (AF), which is one of
the major causes of cardioembolic stroke in elderly. A
prevalence of AF is 0.1% among persons younger than 55
years (44). Similarly, other abnormalities of cardiac struc-
ture of low prevalence in young adults such as cardio-
myopathy, valvular disease, and endocarditis may be cau-
ses of stroke in the young (39).
4. GENETIC DETERMINANTS OF STROKE
IN YOUNG
Stroke is a heterogeneous multifactorial disorder. Stu-
dies conducted in twins, families, and animal models
provide evidence for a genetic contribution to stroke, alt-
hough the real impact of genetics is still unknown (45).
Monogenic Diseases
There are more than 50 single-gene disorders that
may cause stroke. However, they account for less than 1%
of all stroke cases (Table 1). Monogenic disorders are
typically associated with stroke in childhood, with cer-
tain stroke types and subtypes, with the absence of other
stroke risk factors, and with specific phenotypes of the
associated diseases (45). The phenotypic manifestations
of cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leukoencephalopathy (CADASIL)
is one of the most common and extensively studied among
the monogenic diseases (46). CADASIL is associated
with mutations in the NOTCH3 gene (46). The esti-
mated prevalence of CADASIL in young patients with
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Figure 1. Fibromuscolar dysplasia of the carotid artery. An anteropos-
terior view from an angiogram of the left internal carotid artery
showing areas of dilation and stenoses consistent with a „string of
beads” appearance tipical of FMD.
stroke is very low (0.5% of lacunar strokes) (47). Low is
also the percentage of young developing stroke with cere-
bral autosomal recessive arteriopathy with subcortical
infarcts and leukoencephalopathy (CARASIL) (48).
CARASIL is linked to a mutations in the HtrA serine
peptidase 1 (HTRA1) gene (49).
Fabry's disease is a systemic disorder affecting mainly
the kidney, skin, and eye and leading to a painful
neuropathy. Fabry’s disease is linked to a pathogenic
mutations of a-galactosidase enzyme (50). Large-vessel
and small-vessel disease are suggestive of Fabry’s disease.
Studies reported a high frequency of Fabry’s disease in
the young with cryptogenic stroke (51).
An important role in the development of stroke in the
young is played by the Moyamoya disease, a progressive,
occlusive, cerebrovascular arteriopathy, characterized by
bilateral progressive stenosis of the distal internal carotid
arteries or their branches, more commonly involving the
circle of Willis, and the development of compensatory
collateral vessels (52). The Moyamoya disease is rare in
western countries, with an incidence of 0.086 per 100,000
persons per year, while it is more common in African,
American or Asian descendants (up to ten-times more
common in Japan) (52). The disease has two peaks of age
at onset, a juvenile type that occurs at 5 years and an adult
type that occurs at 30–50 years. Adults more often suffer
of hemorrhagic stroke (subarachnoid, intraparenchymal
or intraventricular) caused by the rupture of the col-
lateral vessels that have developed during childhood (45).
Loci for the disorder have been mapped to chomosome
(ch)3p, and ch8q23. Variations in the (ring finger protein
213) RNF213 gene on ch17q25 and mutation in the
actin, alpha 2, smooth muscle, aorta (ACTA2) gene on
ch10q23.3 have also been shown to confer susceptibility
to the Moyamoya disease (45). However, the clear mo-
lecular pathways leading to the Moyamoya disease are
still not well-defined.
Multifactorial Polygenic impact in
stroke
The genetic contribution to stroke seems to be polyge-
nic and based on many alleles that play a cumulative
small effect size. Although limited, candidate gene stu-
dies identified several genetic variants associated with
stoke in different cohort populations (Table 1), such as
common variants in genes for coagulation factor V, pro-
thrombin, methylenetetrahydrofolate reductase (MTFHR),
and angiotensin-converting enzyme (53). A meta-ana-
lysis aimed to determine the genetic risk contributed by
each susceptibility gene polymorphism in adult early-
-onset ischemic stroke patients evaluated twenty-six stu-
dies with age ranges 18–50 years for cases with stroke
(54). The results showed a significant but modest as-
sociation just for 2 polymorphisms on MTHFR C677T
(OR = 1.44, 95% CI = 1.14–1.80) and apolipoprotein E
(ApoE) epsilon2–4 (OR = 2.53, 95% CI = 1.71–3.73).
Genome-wide linkage studies (GWAS) opened a new
era in studing the genetic impact on various diseases.
However, although GWAS have the ability to detect
single risk loci with relatively large effect, not many
GWAS have been conducted in stroke to date, especially
in the young. The first GWAS for IS was conducted
using more than 400,000 unique SNPs in a cohort of 249
patients with ischemic stroke and 268 neurologically
normal controls (55). However, these data did not reveal
any single locus conferring a large effect on risk for
ischemic stroke. In the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) (56),
which consists of four prospective epidemiological co-
horts of nearly 19,600 subjects with 1544 incident strokes,
two SNPs were identified on ch12, in the region of 12p13,
while replication was obtained only for one (rs12425791
SNP; the HR 1.3 fo all stroke, and 1.0 for ischemic
stroke). However, only a small subgroup of young stroke
patients was included in these studies. The Cervical
Artery Dissection and Ischemic Stroke Patients (CADISP)
study (57) and the Genetics of Early Onset Stroke (GEOS)
study (58) that focus on unselected young ischemic stroke
patients are undergoing and will have the opportunity to
address genetic determinants of stroke in the young.
5. OUTCOME AND PROGNOSIS
To date, community based studies have not been very
helpful in increasing our knowledge about the outcomes
and prognosis of stroke in young adults because of the
low incidence of stroke among patients younger than 45.
In the Athens Young Stroke Registry, the probability of
10-year survival in young with stroke was 86.3% (95%CI:
79.1–93.6) and the corresponding probability of com-
posite vascular events was 30.4% (95%CI: 19.6–41.2).
Stroke severity and heart failure were the main predictors
of mortality. At the end of the follow-up period, most
patients (93% of survivors) were functionally indepen-
dent (18). In another study aimed to evaluate the long-
-term clinical outcome in a large series of young adults
(15–45 years) with ischemic stroke the results showed
that among the patients enrolled nine (3%) died as the
result of their initial stroke; two hundred and ten (88%)
were alive with a mean follow-up of 12.3 years and 30
(12%) died during follow-up (59). The average annual
mortality rate was 1.4%, and was higher during the first
(4.9%) compared with the subsequent years (0.9%) after
the initial stroke. Ninety per cent of the followed patients
were functionally independent and 53% returned to work.
Age over 35 years, male gender, the presence of cardio-
vascular risk factors and large-artery atherosclerosis in
the carotid territory were predictors of negative long-
-term outcome after the initial stroke. These data sug-
gested that the long-term prognosis for the ischemic
stroke in the young is better than in the elderly, but the
risk of mortality in young adults with ischemic stroke is
much higher than in the general population of the same
age (59). A recent study showed that severity and out-
come of stroke in children and young adults (up to 40
years) are similar (60).
The Safe Implementation of Thrombolysis in Stroke-
-International Stroke Thrombolysis Register (SITS-ISTR)
Period biol, Vol 114, No 3, 2012. 351
Stroke in young M. J. Katsnelson et al.
was a clinical trial aimed to assess the safety and efficacy
of thrombolysis in 18- to 50-year-old patients with stroke
compared to those aged 51 to 80 years (61). A total of
27,671 patients aged 18–80 years treated with IV alte-
plase within 4.5 hours of symptom onset were enrolled.
The main outcome measures were symptomatic intra-
cerebral hemorrhage (SICH), mortality, and functional
independence (modified Rankin Scale [mRS]) at 3
months. In the 3,246 (12%) patients aged 18–50, SICH
occurred in 0.6% vs 1.9% in those aged 51–80 (OR 0.53;
95% CI 0.31–0.90, p=0.02). Three-month mortality
was 4.9% and 14.4%, respectively (OR 0.49; 95% CI
0.40–0.60, p<0.001) and functional independence was
72.1% vs 54.5%, respectively (OR 1.61; 95% CI 1.43–1.80,
p<0.0001). These results suggest that thrombolysis is
safe in young compared to older stroke patients, and
need to be taken in consideration in treatment of this
subpopulation of ischemic stroke patients.
6. CONCLUSION AND FUTURE
PERSPECTIVES
Stroke in the young is not a rare occurrence. The
factors responsible for stroke in young-adults are quite
different from those that cause stroke in elderly. Arterio-
pathy, cardiac diseases, monogenic disorders and multi-
factorial genetic contributions, in addition to the classical
vascular risk factors, represent potential causes of stroke
in young. Cryptogenic stroke, where the cause cannot be
identified, still accounts for 30% of all ischemic stroke
cases in this sub-population. The advances in the imag-
ing technologies and genetic testing may increase the
identification of the causes and mechanisms of stroke in
young adults. Recent methodologies such as gene ex-
pression profiling, proteomics, metabolomics, and the
next generation whole genome sequencing technologies
aimed at detecting functional changes induced by gene-
tic variations as well as by co-existent non-genetic factor
may further help in addressing the causes of stroke in the
young. Moreover, multicentre registries and randomized
clinical trials specifically dedicated to stroke in the young
may help the scientific community to develop efficient
guidelines for treatment and prevention of stroke in this
important sub-population.
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